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Deciphering of interactions between platinated
DNA and HMGB1 by hydrogen/deuterium
exchange mass spectrometry†
Yuanyuan Wang,a,b Zhifeng Du,*a,d Wei Zheng,a Kui Wu, a Decheng Xu,c Qun Luo,a
Yao Zhao,a Juanjuan Han,a Yangzhong Liu c and Fuyi Wang *a,b
A high mobility group box 1 (HMGB1) protein has been reported to recognize both 1,2-intrastrand crosslinked DNA by cisplatin (1,2-cis-Pt-DNA) and monofunctional platinated DNA using trans-[PtCl2(NH3)
(thiazole)] (1-trans-PtTz-DNA). However, the molecular basis of recognition between the trans-PtTz-DNA
and HMGB1 remains unclear. In the present work, we described a hydrogen/deuterium exchange mass
spectrometry (HDX-MS) method in combination with docking simulation to decipher the interactions of
platinated DNA with domain A of HMGB1. The global deuterium uptake results indicated that 1-transPtTz-DNA bound to HMGB1a slightly tighter than the 1,2-cis-Pt-DNA. The local deuterium uptake at the
peptide level revealed that the helices I and II, and loop 1 of HMGB1a were involved in the interactions
with both platinated DNA adducts. However, docking simulation disclosed diﬀerent H-bonding networks
and distinct DNA-backbone orientations in the two Pt-DNA-HMGB1a complexes. Moreover, the Phe37
residue of HMGB1a was shown to play a key role in the recognition between HMGB1a and the platinated
DNAs. In the cis-Pt-DNA-HMGB1a complex, the phenyl ring of Phe37 intercalates into a hydrophobic
notch created by the two platinated guanines, while in the trans-PtTz-DNA-HMGB1a complex the phenyl

Received 23rd January 2017,
Accepted 3rd April 2017

ring appears to intercalate into a hydrophobic crevice formed by the platinated guanine and the opposite
adenine in the complementary strand, forming a penta-layer π–π stacking associated with the adjacent

DOI: 10.1039/c7dt00275k

thymine and the thiazole ligand. This work demonstrates that HDX-MS associated with docking simulation
is a powerful tool to elucidate the interactions between platinated DNAs and proteins.

rsc.li/dalton

Introduction
cis-Diamminedichloroplatinum(II) (cisplatin) is one of the
widely used anticancer drugs in the clinic, and has been
thought to act by damaging DNA through forming intrastrand
(d(GpG) and d(ApG)) crosslinks.1 While its stereoisomer transdiamminedichloroplatinum(II) (transplatin) is clinically inactive and these two platinum complexes were considered to
be a classical paradigm of the structure–activity relationships.
However, analogues of transplatin in a general structure of
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trans-[PtCl2(NH3)(L)], where L is a planar amine ligand, have
been demonstrated to be cytostatic and active even against
cisplatin-resistant tumor cells.2 A well-known example of such
complexes is trans-[PtCl2(NH3)(thiazole)] (trans-PtTz) (Fig. 1), of

Fig. 1 Chemical structures of platinum anticancer complexes cisplatin
and trans-[PtCl2(NH3)(thiazole)] (trans-PtTz), and the sequences of DNA
segments used in this work. The guanines in bold in strands I and IV
indicate the binding sites for cisplatin and trans-PtTz, respectively.
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which the unique anticancer activity has also been attributed
to DNA damage by forming diverse covalent platinated
adducts, including 1,3-intrastrand, 1,2-interstrand crosslinks,
and monofunctional DNA adducts.3
A high mobility group box 1 protein (HMGB1) containing
domains A and B followed by a long acidic tail was one of the
most important nuclear proteins participating in regulating
numerous nuclear processes.4 A large number of research
studies have shown that HMGB1 can specifically recognize cisplatinated DNA containing a 1,2-GG intrastrand crosslink
which accounts for ∼65% of the total cisplatin crosslinked
DNA.5 X-ray crystallography in combination with mutagenesis
and hydroxyl-radical foot printing has been applied to elucidate the structure of the 1,2-cisplatinated-DNA-HMG-domain
complex, in which the domain A of HMGB1 from rats binds to
a 16 bp double-stranded DNA (dsDNA) containing a single
intrastrand crosslink cis-[Pt(NH3)2{d(GpG)-N7(G8),N7(G9)}].6 A
key binding site found in the cisplatinated-DNA-HMGB1a
complex is the Phe37 residue, which intercalates into a hydrophobic notch formed at the opposite side of the platinum
crosslinked d(GpG) site. Such binding was dramatically
reduced when Phe37 was mutated to alanine.6 Moreover, other
noncovalent interactions such as van der Waals contacts
which involve V35, R23, V19, and A16 of HMGB1a, and hydrogen bonding or salt bridging between HMGB1a, including
K11, S14, Y15, Q20, R23, S41, K42, S45, W48 and K56 residues,
and the cisplatinated DNA were also observed.6
For trans-PtTz, three types of DNA adducts are formed
nearly in equal amounts and it is believed that the cytotoxicity
of trans-PtTz was the sum of all three types of DNA damages
which trigger distinct cellular responses and result in cytotoxicity.7 For instance, the monofunctional trans-PtTz-DNA
adduct could also be recognized by HMGB1,3a and we have
recently demonstrated by mass spectrometric proteomic
studies that the human nuclear protein positive cofactor PC4
specifically binds to 1,3-GNG crosslinked DNA by trans-PtTz.8
However, the detailed molecular basis for the recognition
between these proteins and diﬀerent trans-PtTz-dsDNA
adducts remains largely unclear.
A hypothesis proposes that the monofunctional DNA
adducts by trans-PtTz may create a local conformational distortion similar to that in the 1,2-GG crosslinked DNA by cisplatin,
and the planar thiazole ligand might intercalate into the
duplex and stack with aromatic rings of bases. As a consequence, the targeted DNA duplex would unwind and bend,
similar to that resulting from the 1,2-GG cisplatinated crosslinking.9 Although the monofunctional trans-PtTz-DNA has
been shown to be recognized by HMGB1,3a little information
has been gained to elucidate the molecular basis of this recognition. Therefore, in the present work we have developed a
hydrogen/deuterium exchange mass spectrometry (HDX-MS)
method to investigate the interactions, particularly binding the
epitope of HMGB1a to mono-platinated DNA by trans-PtTz.
HDX-MS elucidates the conformation and dynamics of proteins, protein–protein and protein–ligand interactions, and
localizes the binding regions (or sites), in particular noncova-
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lent binding sites of ligands to proteins.10 Of the many
diﬀerent kinds of hydrogen atoms in proteins, only the hydrogens located at the peptide backbone amide linkages (NHs)
have exchange rates with deuterium in solution within a range
that can be easily measured by MS. The backbone amide
hydrogens involved in the formation of weak hydrogen bonds
or located at the surface of the protein can exchange rapidly,
whereas those buried in the interior or those involved in
strong hydrogen bonds exchange more slowly. By measuring
HDX rates of backbone amides after being quenched at low
pH and low temperature one can obtain structural information
on protein dynamics and conformation. In the cases of
probing protein–ligand interactions using HDX-MS, the diﬀerence in global deuterium uptake between the native proteins
and the ligated proteins can be indicative of the interactions
between the proteins and the ligands as some solventaccessible amides located within the interaction regions are
shielded from deuterium exchange, retarding the global deuterium uptake of the proteins.11 Furthermore, spatial resolution in the range of 1–10 residues can be obtained by coupling
mass spectrometry with proteolytic digestion by pepsin under
the HDX quenching conditions following separation of high
performance liquid chromatography (HPLC). The kinetic analysis of deuterium uptake of an individual peptide and/or the
local deuterium uptake will then reveal the binding sites
(or regions) of the protein–ligand complex.10b,12

Results and discussion
Global hydrogen/deuterium exchange
The HMGB1 protein consists of two domains (domain A
termed as HMGB1a and domain B as HMGB1b) and an acidic
C-terminal with a short lysine-rich A–B linker and a 23-aminoacid B–C linker.13 Reports have shown that full-length HMGB1
as well as HMGB1a/HMGB1b can all specifically bind to the
1,2-GG or AG intrastrand crosslinked DNA by cisplatin14 and
HMGB1a is the core to dominate such specific binding.15
HMGB1a also showed relatively higher aﬃnity to DNA containing a monofunctional bound trans-PtTz than HMGB1b.3a
Therefore in this work only the HMGB1a domain was chosen
for the investigation of interactions with platinated DNA, 1,2cis-Pt-III and 1-trans-PtTz-VI (Fig. 1) of which the details of
preparation are given in the Experimental section.
Firstly, the global deuterium uptake of HMGB1a with and
without binding to platinated DNA adducts was measured and
compared. Global HDX is often the first step of an HDX experiment to find out if a particular ligand has an eﬀect on the secondary and tertiary structure of a protein.16 Our first attempt
to obtain global HDX data on HMGB1a with an excess of platinated DNA adducts by ESI-MS coupled with reversed-phase
liquid chromatography failed due to the lack of protein
signals. Following various times of incubation in 90% D2O, the
deuterated protein is placed in a low pH (e.g. pH 2.5) buﬀer at
low temperature (≈2 °C) to quench the H/D exchange during
subsequent HPLC separation and electrospray ionisation mass
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spectrometry (ESI-MS) analysis. As low pH (≈2.5) is required
for quenching H/D exchanges, most of the proteins should be
positively charged as all carboxylic groups ( pKa ≈ 4.6) will be
eﬀectively protonated, leaving only basic amino acids positively charged. DNA and RNA, on the other hand, will still have
a substantially negative net charge due to the presence of the
phosphate backbone. Hence, the low pH may result in the formation of stable protein/nucleic acid precipitates which in
turn interfere with the HPLC separation of protein–DNA complexes and mass spectrometric analysis of the proteins.17
Usually, there were two methods to solve this signal suppression problem: applying a strong anion exchange (SAE) column
to trap the nucleic acids18 or using protamine sulfate to precipitate nucleic acids.17 Given that the SAE trap extends the
time of HPLC-MS analysis, herein we chose protamine sulfate
to precipitate excess of DNA prior to HPLC-MS analysis. As
shown in Fig. S1 in the ESI,† even with 10-fold excess of 1,2cis-Pt-III, the obvious mass spectrum of HMGB1a could be
obtained. The deuterium uptake of unligated HMGB1a was
measured to be (27.7 ± 1.0) and (27.4 ± 1.2) in the absence and
in the presence of protamine sulfate (data not shown here),
which means that there is no eﬀect of protamine sulfate on
the HDX reactions of HMGB1a.
The apo-HMGB1a (unligated) approached the maximum
numbers of deuterium after ca. 5 min of HDX at 295 K
(Fig. 2a), suggesting the fast-exchanging of backbone amido
hydrogens of HMGB1a without any ligands. The maximum
mass shift of 40 Da is less than the number of amido hydrogens available for deuterium incorporation (72). The ratio of
deuteration (55.6%) is less than the percentage (90%) of D2O
used in the buﬀer, most probably attributed to the substantial
back exchange of hydrogens from H2O and/or the local hiding
of amido hydrogens from the solvent. For HMGB1a, such a low
deuterium exchanging rate was mainly attributed to the three
stable α-helices (Fig. S2, ESI†).
Due to the binding of the cisplatinated DNA (1,2-cis-Pt-III),
the deuterium uptake of the holo-HMGB1a (ligated) at 5 s
significantly decreased to 6.7, which is 27% less than that of
apo-HMGB1a (Fig. 2a). With the elevation in incubation time,

Paper

the exchanging deuterium number of holo-HMGB1a gradually
increased and reached 36 at 32 min, but still a little lower than
the incorporated deuterium (39.5) of apo-HMGB1a with the
same incubation time. These indicate that the conjugation of
the cisplatin-intrastrand crosslink to HMGB1a significantly
shielded the backbone amido hydrogens of the protein from
exchanging with deuterium in solution.
Similar situation has been observed for the HDX of
HMGB1a ligated with the monofunctional DNA (1-transPtTz-VI) under the same conditions (Fig. 2a). Moreover,
HMGB1a bound to 1-trans-PtTz-VI showed much less deuterium incorporation (26.3) than those of apo-HMGB1a (39.5)
and holo-HMGB1a (36) with 1,2-cis-Pt-III at 32 min. The HDX
rate as pseudo-first order reactions of the apo-HMGB1a, and
HMGB1a ligated with 1,2-cis-Pt-III and 1-trans-PtTz-VI are
calculated to be (4.0 ± 0.8) × 10−2, (1.0 ± 0.1) × 10−3, and
(9.1 ± 1.3) × 10−4 s−1, respectively, based on the kinetic curves
of HMGB1a in diﬀerent states (Fig. 2a). These indicate that the
binding aﬃnity of the monofunctional DNA by trans-PtTz to
HMGB1a is similar to that of the cisplatin crosslinked DNA to
the protein, consistent with the previous report.3a Such similarity between the HDX reactions of HMGB1a bound to the
two platinated DNA also suggests that the mono-functional
binding of trans-PtTz to DNA causes similar distortion of DNA
structure to that induced by bifunctional binding of cisplatin.
Electrophoretic mobility shift assays (EMSAs) were performed to provide an additional quantitative view of the
binding aﬃnity of HMGB1a towards diﬀerent damaged DNA
segments. Fluorescein-labeled 1,2-cis-Pt-III and 1-trans-PtTz-VI
were prepared as described in the Experimental section. The
EMSA results are displayed in Fig. 2b. In each gel, lane 1 contains 0.1 μM of 1,2-cis-Pt-III or 1-trans-PtTz-VI in the absence of
HMGB1a, lanes 2–7 correspond to the Pt-DNA-HMGB1a complexes generated in the presence of various concentrations of
the protein. As shown in Fig. 2b, the shift of both of the platinated DNA segments were significantly retarded due to the
presence of HMGB1a, indicating the formation of PtDNA-HMGB1a complexes. However, there were no hysteretic
bonds observed in all lanes even in the presence of 10-fold
excess of HMGB1a. This may be attributed to the charge neutralization of the negatively charged DNA segments by
HMGB1a ( pI: 9.5819) under the given pH (8.1). According to
the EMSA data, there is no pronounced diﬀerence in the
binding aﬃnity of HMGB1 to the two platinated DNA segments. This suggests that HDX-MS is more sensitive for
probing the binding aﬃnity of platinated DNA to proteins.
Local hydrogen/deuterium exchange

Fig. 2 (a) Kinetic curves for the global deuterium incorporation of nonligated HMGB1a (─□─) and ligated HMGB1a with 1,2-cis-Pt-III (─○─) or
1-trans-PtTz-VI (─Δ─). (b) EMSAs for 0.1 μM of 1,2-cis-Pt-III (top panel)
and 1-trans-PtTz-VI (bottom panel) in the presence of HMGB1a. The
concentrations of HMGB1a for lane 1–7 were 0, 0.1, 0.2, 0.4, 0.6, 0.8
and 1 μM, respectively.

This journal is © The Royal Society of Chemistry 2017

Local deuterium uptake studies can expand the resolution of
mapping the binding sites of protein–ligand complexes to a
short peptide level. To decipher the binding epitope of platinated DNA to HMGB1a, a peptide mass fingerprint (PMF) of
apo-HMGB1a was firstly generated by HPLC-ESI-MS analysis
following the pepsin digestion of the protein. Six peptides
labeled as T1–T6 with only Met62 missed were identified
(Table 1) with suﬃcient signal-to-noise ratios. Exact masses of
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Peptide
T1
T2
T3
T4
T5
T6

Dalton Transactions
Peptides identiﬁed by HPLC-ESI-MS analysis of peptic digest of HMGB1a

Sequence & positiona

Observed m/z

S5NAPRGKMSSYAF17
S14YAFFVQTCREEHKKKHP31
Q20TCREEHKKKHPDASVNFSEFSKKCSERWKTMSAKEKGKFED61
H26KKKHPDASVNFSEFSKKC44
S41KKCSERWKT50
A63KADKARYEREMKTY77

2+

708.3406
559.53454+
626.31638+
444.22595+
626.83042+
930.46562+

Theoretical m/z
2+

708.3405
559.53364+
626.32038+
444.23055+
626.82812+
930.47662+

δ (ppm)

Method

0.14
1.61
6.39
10.35
3.67
11.82

MS/MS
Exact mass
Exact mass
Exact mass
Exact mass
Exact mass

a
The sequence and the secondary structural elements of HMGB1a is shown in Fig. S2. The sequence position follows the X-ray crystal structure
reported previously (PDB code: 1CKT).6

these peptides were determined through adding internal standards, substance P (m/z 674.8672, z = 2+) to the digested
sample. The experimentally measured peptide masses were
matched with the calculated masses of peptides using the
FindPept software20 within a 20 ppm error. In cases where
mass matching gave more than one hit within a 20 ppm
window, peptide sequences were identified by MS/MS analysis.
As HMGB1a is hydrophilic, a high sequence coverage of 99%
was achieved (Fig. S2, ESI†), providing adequate structural
information for localizing the interaction regions between
HMGB1a and platinated DNA fragments.
Next we measured the deuterium uptake of an individual
peptic peptide of apo-HMGB1a and holo-HMGB1a ligated with
platinated DNAs. The typical ESI mass spectra of peptides T1
(S5–F17), T2 (S14–P31), T3 (Q20–D61), T4 (H26–C44) and T5
(S41–T50), derived from apo- and holo-HMGB1a ligated with
1,2-cis-Pt-III subjected to 1 min continuous HDX at 295 K, are
shown in Fig. 3a, b and S3.† The kinetic plots over a 10 min
time course for the five peptides are shown in Fig. S4.† The
peptic peptide T6 (A63–Y77) showed no change in deuterium
uptake between apo- and holo-HMGB1a (data not shown).
Amido hydrogens involved in α-helix will exchange more
slowly than those that are unstructured and not involved in
hydrogen bonding. The peptides T1–T5, which have some
sequence overlap through the three helices, all displayed a pronounced decrease in deuterium uptake upon the complexation
of HMGB1a with 1,2-cis-Pt-III, indicating that all these regions
were involved in the recognition with the damaged DNA. After
1 min deuteration, the deuteration ratios of T1–T5 derived
from the 1,2-cis-Pt-III-HMGB1a complex were 36.5%, 33.3%,
15.7%, 28.8% and 11.0%, respectively, significantly lower than
those of T1–T5 (53.5%, 65.2%, 33.0%, 54.3% and 46.4%,
respectively) derived from apo-HMGB1a (Table S1 and Fig. 3c,
S4, ESI†). This means that about 1.7, 4.6, 6.2, 4.4 and 2.5
amido hydrogens, respectively, in T1–T5 were excluded from
exchanging with D2O due to the binding of the cisplatinated
DNA to HMGB1a. After 10 min HDX, the deuteration ratios of
T1–T5 from the holo-HMGB1a increased to 55%, 70.8%,
42.9%, 55.9% and 45.8%, respectively (Table S1 and Fig. S4,
ESI†). In particular, the deuteration ratios of T2 and T3 were
nearly the same as those of T1 and T2 derived from apoHMGB1a. Accompanied by these, the excluded amido hydrogen number was decreased to 1.2, 0.6, 1.0, 1.3 and 1.1, respect-
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Fig. 3 (a, b) Mass spectra of peptic peptides T1 (S5–F17) and T3 (Q20–
D61). (i) Non-deuterated peptides; (ii) deuterated peptides of nonligated HMGB1a and (iii) deuterated peptides of ligated HMGB1a with
1,2-cis-Pt-III after incubated in D2O buﬀer for 1 min. (c) Deuterium
incorporation (%) of peptic peptide of HMGB1a with and without platinated DNA, showing a slowed HDX rate upon platinated DNA binding
except for the C-terminal region after being incubated in D2O buﬀer for
1 min.

ively, for T1–T5 in the holo-HMGB1a. The deuteration rates of
T1 (S5–F17) and T5 (S41–T50) in holo-HMGB1a were slower
than those of the other three peptides, indicating stronger
interactions of these regions with cisplatinated DNA.
In the crystal structure of the 1,2-cis-Pt-III-HMGB1a
complex,6 all the three helices are involved in the interaction
with the cisplatinated DNA through diﬀerent ways. The helix I
mainly interacts with the sugar–phosphate backbone at the
unmodified part of the DNA duplex, helix II mainly interacts
with the backbone of the platinated part, while helix III has
weaker interactions with only one water-mediated contact with
the platinated DNA duplex. This explains the lack of HDX variations of T6 between apo- and holo-HMGB1a with 1,2-cis-Pt-III
observed here.
Utilizing the same HDX-MS method described above, we
studied the deuteration of holo-HMGB1a ligated with 1-trans-

This journal is © The Royal Society of Chemistry 2017
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PtTz-VI. After 1 min HDX, the deuteration ratios (%) of T1–T5
in the holo-HMGB1a were measured to be 46.4, 32.7, 24.1, 33.7
and 28.1, respectively (Table S1 and Fig. 3c, S5, ESI†).
Compared to those of the respective peptides (59.2, 65.7, 34.9,
60.5 and 41.9, respectively, Table S1†) in the apo-HMGB1a, we
calculated that about 1.3, 4.8, 3.9, 4.1 and 1.0 amido hydrogens, respectively, in T1–T5 were excluded from exchanging
with D2O due to binding to 1-trans-PtTz-VI.
Except for T3, the deuteration ratios of the other four peptides in the holo-HMGB1a are still significantly lower than
those of the respective peptides from apo-HMGB1a after
10 min of deuteration (Fig. S5, ESI†). In particular, the deuterium incorporation of T2 (S14–P31) in the holo-HMGB1a was
ca. 20.3% less than that of T2 in the apo-HMGB1a. These
results imply a closer contact of 1-trans-PtTz-VI with HMGB1a
than 1,2-cis-Pt-III in the region of S14 to P31 residues. Based
on the HDX rates at the peptide level, the 1-trans-PtTz-VI
adduct binds to HMGB1a on the region involving peptides T2,
T4 and T5, of which the sequence covers residues through S14
to F50 and spans helix I, loop 1 and helix II. This is similar to
the binding region of the 1,2-cis-Pt-VI adduct to HMGB1a as
revealed by our HDX-MS analysis (vide supra) and X-ray crystallographic characterization reported previously.3a,21 However,
as the detailed conformation of 1-trans-PtTz-VI binding to
HMGB1a may be diﬀerent from that of 1, 2-cis-Pt-III-HMGB1a
binding to HMGB1a (vide infra), the changes in the HDX rate
of individual peptic peptide derived from HMGB1a induced by
the binding of 1-trans-PtTz-VI were slightly diﬀerent from
those induced by the binding of 1, 2-cis-Pt-III (Table S1, ESI†).
It is notable that under the given conditions, the peptic
peptides of HMGB1a were generally long (Table 1), which does
not allow exact identification of the binding sites at the amino
acid resolution of 1-trans-PtTz-VI to HMGB1. To achieve this
goal, molecular docking simulations were next performed.
Docking simulations
The X-ray crystal structure of 1,2-cis-Pt-III-HMGB1a complex
(PDB code: 1CKT)6 was used to develop and validate the
docking simulation strategy. The 3D molecular models of
HMGB1a and 1,2-cis-Pt-III were re-constructed by extracting
the respective molecule from the crystal structure following
energy-minimization. Then, the 1,2-cis-Pt-III molecule was
docked back into the HMGB1a receptor following the procedure described in the Experimental section. The resulting
molecular model (Fig. 4a and c) shows that the region of
HMGB1a spanning helix I, loop 1 and helix II is involved in
the binding to 1,2-cis-Pt-III, and that both the helices lie on
the minor groove next to the major groove housing the platinated site of the cisplatinated duplex (Fig. 4a and c). The conformation of the 1,2-cisplatin crosslinked duplex binding to
HMGB1a in the molecular model superimposes well onto that
of the platinated crosslink binding to HMGB1a in the crystal
structure (Fig. S6, ESI†). As shown in the enlarged view of the
molecular model (Fig. 4a), the Phe37 residue intercalates into
the hydrophobic cleft created by the two platinated guanines
(G7 and G8), also consistent with the X-ray crystallographic

This journal is © The Royal Society of Chemistry 2017
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Fig. 4 The conformers/poses in diﬀerent views of (a, c) 1,2-cis-Pt-III
and (b, d) 1-trans-PtTz-VI interacting with HMGB1a generated by
docking simulation. The enlarged views in a and b depict the intercalation of the Phe37 residue between bases G8 and G9 in the 1,2-cis-Pt-IIIHMGB1 complex and between G7 and A19 in the 1-trans-PtTz-VIHMGB1a complex, respectively.

results previously reported.6 Moreover, a similar hydrogen
bonding network, which mainly involves Ser41, Lys42, Ser45
and Trp48 residues of HMGB1a, was observed between the
molecular model and the crystal structure of the 1,2-cis-Pt-IIIHMGB1a complex (Fig. 4a and S7, ESI†). These suggest that
the docking simulation method used herein is applicable, so
the monofunctional platinated duplex 1-trans-PtTz-VI was
docked into HMGB1a following the same procedure described
above. Surprisingly, the resulting molecular model demonstrates that 1-trans-PtTz-VI binds to HMGB1a with a totally
diﬀerent orientation from that of 1,2-cis-Pt-III to the protein
(Fig. 4b and d), though both of them interact with HMGB1a in
a similar region. The helices I and II appear to ride between
the minor groove and the adjacent major groove containing
the platinated site (G7) (Fig. 4b and d). Similar intercalation of
the Phe37 residue into the minor groove of the transplatinated
duplex was also observed in the model of the 1-trans-PtTz-VIHMGB1a complex, but Phe37 appears to insert into the hydrophobic crevice formed by the platinated G7 and non-modified
A19 in the complementary strand (Fig. 4b), leading to the formation of a quintuplicate π–π stacking involving T8, triazole
ligand, G7, Phe37 and A19. Compared with the 1,2-cis-Pt-IIIHMGB1a complex, more hydrogen bonds are observed in the
1-trans-PtTz-VI-HMGB1a complex, which involve residues
Tyr15, Gln20, Arg23, Val35, Asn36, Ser38, Lys42 and Lys58 of
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decrease in deuterium incorporation of the N-terminal, helix I,
loop 1 and helix II even after 10 min of HDX, while the binding
of the cisplatinated duplex reduced only the HDX rate of loop 1
and helix II. This is in line with the docking simulation results
that the binding of 1-trans-PtTz-VI to HMGB1a leads to the formation of a stronger π–π stacking and more H-bonds between
the protein and modified DNA than the binding of 1,2-cis-Pt-III
to the protein, implying that 1-trans-PtTz-VI binds to HMGB1a
more tightly than 1,2-cis-Pt-III.

Conclusions

Fig. 5 The conformations of HMGB1a ligated with (a) 1,2-cis-Pt-III and
(b) 1-trans-PtTz-VI are generated by docking simulation. The dotted
yellow lines illustrate the positions of H-bonding interactions between
HMGB1a and the platinated DNAs.

HMGB1a (Fig. 5b). Among these residues, only Lys42 is found
to form H-bonds with both the cisplatinated and the transplatinated DNA adducts. This again indicates that the transplatinated duplex takes a diﬀerent orientation from the cisplatinated duplex to bind to HMGB1a, leading to the formation of
more H-bonds than the binding of the cisplatinated duplex to
the protein.
Combined the local HDX-MS and the docking simulation
results described above, we render the deuterium incorporation
map of HMGB1a alone, 1,2-cis-Pt-III-HMGB1a and 1-trans-PtTzVI-HMGB1a complexes to depict the binding regions of 1,2-cis-PtIII and 1-trans-PtTz-VI to HMGB1a in terms of HDX slowing of
amido hydrogens in HMGB1a. The results (Fig. 6) indicate that
the binding of the transplatinated duplex led to a pronounced

In summary, we have developed a HDX-MS method in combination with molecular docking simulation to investigate the
noncovalent interactions between HMGB1a and mono-platinated DNA duplex by trans-PtTz with the binding of the cisplatinated DNA crosslink to the protein as a reference. The global
HDX-MS analysis allows evaluating the binding aﬃnity of the
protein to the platinated DNA duplexes, and local HDX-MS
probing at the peptide level enables mapping the interaction
regions (sites) of the protein receptor with the modified DNA
ligands. Furthermore, molecular docking simulation provides
the conformation and pose in details of the receptor–ligand
complexes to verify the experimental results obtained by
HDX-MS analysis. The results reveal that HMGB1a binds to the
mono-functional modified DNA duplex in a distinct mode
from that to the cisplatin-crosslinked DNA duplex, though the
modified DNA duplexes bind to HMGB1a in a similar region
involving residues through S14 to F50 spanning helix I, loop
1 and helix II of the protein. The Phe37 residue was demonstrated to play a key role in the interaction of HMGB1a with
both of the modified DNA segments, inducing the formation
of a triple-layer and a penta-layer π–π stacking in the 1,2-cis-PtIII-HMGB1a and 1-trans-PtTz-VI-HMGB1a complexes, respectively. Moreover, the binding of 1-trans-PtTz-VI to HMGB1a
leads to the formation of more H-bonds than that resulting
from the binding of 1,2-cis-Pt-III to the protein. These together
make 1-trans-PtTz-VI bind to HMGB1a more tightly than 1,2cis-Pt-III. The present work demonstrates that HDX-MS in combination with molecular docking simulation is a powerful tool
to elucidate the noncovalent interactions between proteins
and damaged DNA by metallodrugs, and is anticipated to
provide insights into better understanding of the molecular
basis of recognition between proteins and DNA lesions.

Experimental section
Materials
Fig. 6 Deuterium incorporation mapping of HMGB1a in the nonligated form, and in 1,2-cis-Pt-III-HMGB1a and 1-trans-PtTz-VIHMGB1a complexes after being incubated with 90% D2O for 10 min. The
maps were rendered by Pymol program based on HDX-MS data, and
depict the interactive regions in terms of HDX slowing in helix II and
loop 1 (1,2-cis-Pt-III-HMGB1a), or in helices I, II and loop 1 (1-transPtTz-VI-HMGB1a).

6192 | Dalton Trans., 2017, 46, 6187–6195

Pepsin was purchased from Sigma-Aldrich and used without
further purification. Deuterium oxide (99.8%) was purchased
from Norell Inc. (Landisville, NJ, USA) and protamine sulfate
from Sigma. Formic acid (FA) was bought from Acros
(Belgium); tetraethylammonium acetate (TEAA, 1 M) from
AppliChem (Germany) and acetonitrile (HPLC grade) from
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Merck (Germany). Complementary single-stranded oligonucleotides (ONTs) I (5′-CCTCTCTGGACCTTCC-3′) and II
(5′-GGAAGGTCCAGAGAGG-3′), IV (5′-CCTCTTGTCTCC-5′) and
V (5′-GGAGACAAGAGG-3′) were obtained from TaKaRa (Dalian,
China). Cisplatin was purchased from Alfa Aesar and trans[PtCl2(NH3)(thiazole)] (trans-PtTz) (Fig. 1) was prepared following the procedure reported previously.22 Aqueous solutions
were prepared using MilliQ water (Milli-Q Reagent Water
System).
Expression and purification of HMGB1a
The cDNAs encoding the HMGB1 domain A were prepared by
means of PCR from a human bone marrow cDNA library and
cloned into the vector LIC-SG1. The protein was expressed in
gold cells. Cells were grown in 1 liter of LB with 1 μg mL−1
ampicillin to an OD600 of 0.6 at 310 K, and induced with
0.8 mM isopropyl β-D-thiogalactoside. The cells were allowed to
grow for 5 hours before harvesting. The cell pellets were
thawed in 200 mM NaCl/20 mM Tris buﬀer ( pH 8) and lysed
by sonication. The protein was extracted from the lysates by
Ni2+ aﬃnity chromatography (Qiagen). The Ni2+ aﬃnity beads
were washed three times with 10 column volumes of buﬀer
containing 200 mM NaCl, 50 mM Tris and 30 mM imidazole
( pH 8), and the proteins were eluted with 10 column volumes
of 250 mM imidazole in the same buﬀer. The His-tag was
removed by cleavage by TEV protease at 16 °C overnight. The
final purification of HMGB1a was performed by FPLC purification on a Hiload Superdex 75 column (GE Health) and
protein concentrations were determined by UV-Vis
spectroscopy from the absorbance at 280 nm using ε =
9970 M−1 cm−1.
Preparation of platinated DNA
The platinated single-stranded ONT I by cisplatin was prepared
as described in the literature.23 Briefly, cisplatin was incubated
with the -GG- strand at a molar ratio of Pt/I = 0.8 : 1 at 310 K
for 3 days. Then the platinated strand was purified by HPLC
using a C8 column (4.6 × 250 mm, 5 μm, Agilent) on an Agilent
1200 HPLC system where the mobile phases were water containing 20 mM TEAA (solvent A) and acetonitrile containing
20 mM TEAA (solvent B). The HPLC fraction containing the
cisplatinated strand was collected, lyophilized and then
characterized by MALDI-TOF-MS (Fig. S8a, ESI†). The concentration of the purified cisplatinated strand I was measured by a
2550 UV-VIS spectrometer (Shimadzu, Japan). The cisplatincrosslinked double-stranded ONT III (1,2-cis-Pt-III) was prepared by hybridization of the purified cisplatinated strand
I with equiv. molar complementary strand II in 100 mM
NaClO4. The formation of double-stranded ONT containing
cisplatin lesion sites was confirmed by circular dichroism (CD)
spectroscopy and FT-ICR-MS (Fig. S8c and e, ESI†).
The monofunctional platinated single-stranded ONT IV by
trans-PtTz, of which the formation was confirmed by ESI-QTOF-MS analysis (Fig. S8b, ESI†), and the double-stranded
ONT VI containing the trans-PtTz modified site were prepared
following a similar procedure described above. The formation
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of double stranded ONT containing trans-PtTz binding site was
confirmed by CD spectroscopy and FT-ICR-MS (Fig. S8d and f,
ESI†).
Electrophoretic mobility shift assay
Fluorescein-labeled single-stranded ONTs, designated as F-II
and F-V, were obtained from Sangon Biotech (Shanghai,
China). Fluorescein-labeled 1,2-cis-Pt-III and 1-trans-PtTz-VI
were obtained by annealing 1,2-cisplatinated I with 1 mol
equiv. F-II and the mono-functional platinated ONT IV with
1 mol equiv. F-V, respectively. For EMSA experiments, an
aliquot (1 μL) of the fluorescent labeled double-stranded
1,2-cis-Pt-III (1 μM) or 1-trans-PtTz-VI (1 μM) was mixed with
various volumes of HMGB1a protein (15 μM), and the binding
buﬀer (20 mM HEPES, 50 mM NaCl, 5 mM MgCl2 and 10%
(w/v) glycerol) was added to make a final volume of 10 μL. The
mixtures were incubated at room temperature for 2 h prior to
sampling. The protein–DNA complexes were separated in 6%
non-denaturing polyacrylamide gels in 1× Tris-borate-EDTA
buﬀer ( pH 8.1) run at 50 V at 4 °C for 60 min. After electrophoresis, the gels were excited at 488 nm wavelength and
recorded at 600 nm by scanning with a Typhoon TRIO Variable
Mode Imager (GE Health).
Hydrogen/deuterium exchange protocol
Firstly, HMGB1a (232 μM) was incubated with 2 equiv. mol of
1,2-cis-Pt-III or 1-trans-PtTz-VI in buﬀer ( pH 7.4) containing
20 mM HEPES and 200 mM NaCl at 295 K for 32 min to form
a respective HMBG1a-platinated DNA complex. For global deuterium uptake, 27 μL of D2O was added to 3 μL of HMGB1a
alone or each HMGB1a-platinated DNA complex to initiate
H/D exchange. At various times, the HDX was quenched with
3 μL ice-cold FA (20%) containing diﬀerent concentrations of
protamine sulfate, which was used to remove excess of platinated DNA from the DNA-HMGB1a complexes prior to MS analysis, to give a final pH of 2.5, and a 10 : 1 ratio (m/m) of protamine sulfate/DNA. The deuterated protein was loaded immediately onto a CAPCELL PAK C8 column (1.0 × 35 mm, 300 Å,
Shiseido). The column was washed with 1% solvent B (273 K)
for 2 min at a flow rate of 37 μL min−1, which allowed backexchanging of the labile sites of the protein. Then, a gradient
of 53–80% solvent B within 7.5 min was used to elute the
protein directly into the mass spectrometer.
For local deuterium uptake, the HDX reaction of HMGB1a
or HMGB1a-platinated DNA complexes was quenched by 20%
FA mixed with isovolumetric pepsin (2 μg μL−1 in H2O) at
diﬀerent times. The digestion was conducted at 273 K for
3 min, then the peptic digests was loaded on a symmetry-C18
column (1.0 × 50 mm, 100 Å, 3.5 μm, Waters). The column was
washed with 5% solvent B (273 K) at 37 μL min−1 for
2 minutes, back-exchanging the deuterium in labile sites of
the peptides. The peptides were then separated with a LC gradient (10 to 35% B over 3 min, 35 to 80% B over 0.5 min) and
infused directly to a mass spectrometer. The deuterium incorporation percentage of each peptide was determined from the
centroid of the molecular ion isotope peaks using the
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HX-Express software.24 The deuterium percent was calculated
by using the equation as follows:

Published on 03 April 2017. Downloaded by Virginia Commonwealth University on 27/07/2017 20:26:59.

Deuterium% ¼

MHDX  Mcontrol
 100%
ðN  2Þ  0:9

where mHDX is the centroid mass of the deuterated peptides,
mcontrol is the centroid mass of the nondeuterated peptides,
(N − 2) is the number of exchangeable amide hydrogens, and
0.9 is the final D2O content of the buﬀer system.
Electrospray ionization mass spectrometry coupled with liquid
chromatography
Positive-ion electrospray ionization mass spectrometry analysis
was performed on a Micromass Q-TOF ultima global mass
spectrometer (Waters) coupled to a Waters CapLC system.
Mobile phases were A: 95% H2O containing 4.9% acetonitrile
and 0.1% formic acid (FA), and B: 95% acetonitrile containing
4.9% H2O and 0.1% FA. The injector, loop, column and solvents were cooled to 2 °C to minimize back-exchange using a
home-made low temperature box (50 × 50 × 50 cm) maintained
at 2 (±0.2) °C by a refrigeration compressor. For mass spectrometry analysis, the desolvation temperature was 413 K and
the source temperature was 353 K. Nitrogen was used as both
cone gas and desolvation gas with a flow rate of 40 L h−1 and
400 L h−1, respectively. The collision energy was set up to
10 eV. Global deuterium uptake spectra were acquired in the
range of m/z 500–2500. Local deuterium uptake spectra were
obtained in the range of m/z 400–1800. MassLynx (ver. 4.0)
software was used for analysis and post data processing.
Docking simulation
The crystal structure of HMGB1a ligated with a 1,2-GG intrastrand crosslink (1,2-cis-Pt-III) was obtained from the Protein
Data Bank (code: 1CKT)6 to reconstruct the 3D molecular
models of the 1,2-cis-Pt-III-HMGB1a complex. The 3D molecular model of the monofunctional platinated double strand
VI by trans-PtTz (1-trans-PtTz-VI) was constructed in Sybyl X1.1
(Tripos Inc.). The docking simulations between HMGB1a and
each platinated DNA adduct were performed on Hex 8.0.0 software (http://www.loria.fr/~ritchied/hex/).25 The platinated DNA
molecule (moving molecule) was systematically moved within
the shape of the protein to match H-bonding interactions and
hydrophobic contacts between the receptor and the ligand,
and electrostatic potentials were then calculated for the
HMGB1a protein (stationary molecule). The docking correlation type was set as shape and electron, receptor range and
ligand range were all set as 90°. The resulting molecular
models were reconstructed by Sybyl X1.1 and/or Pymol
ver1.1r153.
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